Nadine Al-Naamani, M.D., M.S., Aldrighetti Research Award for Young Investigators Grant Recipient, Shares Research Journey and Hope for the Future

2018-04-13T14:26:59+00:00 April 11th, 2018|

Nadine Al-Naamani, M.D., M.S., University of Pennsylvania, and Andrew Sweatt, M.D., Stanford University, were the research awardees of the 2017 Aldrighetti Research Award for Young Investigators and PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension, respectively. In this two-part series, the 2017 PHA Research Program awardees detail their journey to PH, and their hopes for

Study Finds Inhaled Nitric Oxide May Benefit Patients with COPD and Pulmonary Hypertension

2018-04-11T15:26:35+00:00 April 11th, 2018|

by Phyllis Hanlon, Contributing Writer   The Centers for Disease Control and Prevention (CDC) reports that about 15.7 million people in the U.S. have been diagnosed with chronic obstructive pulmonary disease (COPD). The CDC noted in 2014 that this disease was the third leading cause of death in the U.S. Previous research has estimated that between

2017 PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension Award Grantee Discusses Work and Research

2018-04-09T19:20:14+00:00 April 6th, 2018|

Andrew Sweatt, M.D., Stanford University, and Nadine Al-Naamani, M.D., M.S., University of Pennsylvania, are the research awardees of the 2017 PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension and Aldrighetti Research Award for Young Investigators, respectively. In the first of a two-part series, Dr. Sweatt discusses his research journey, grant awarded study and involvement with the

Pulmonary Hypertension Association Registry Gives People Living with Deadly Lung Disease a Chance to Advance Patient Care

2018-03-26T18:28:00+00:00 March 26th, 2018|

Silver Spring, Md. (March 23, 2018) – The Pulmonary Hypertension Association (PHA) patient registry is giving more than 500 people with two deadly, often-misdiagnosed breathing diseases a way to advance patient care – for themselves and others. The national nonprofit established the PHA Registry (PHAR) in 2015 as part of its PH Care Center (PHCC)

Are Two Drugs Better Than One for PAH?

2018-03-23T19:18:55+00:00 March 23rd, 2018|

by Phyllis Hanlon, Contributing Writer   Research in managing WHO Group 1 PH (PAH, pulmonary arterial hypertension) has resulted in new drugs and strategies that have extended and are improving life for patients. Lately, some doctors have started prescribing more than one drug for patients. Researchers from Brazil and France teamed up to examine how

Assessing Risk in Patients with Pulmonary Arterial Hypertension

2018-03-01T15:39:37+00:00 March 1st, 2018|

Although the past decades of discovery and research have yielded drugs that improve prognosis and quality of life, the long-term survival rates for people living with PAH is still unacceptably low. A recent editorial offers thoughts on assessing risk for people living with this disease. by Phyllis Hanlon, Contributing Writer   In the past decades of

PHA Accreditation Program Assures Access to Specialized Care for Thousands With Often-Misdiagnosed Deadly Lung Disease

2018-02-16T16:07:20+00:00 February 16th, 2018|

Silver Spring, MD (February 15, 2018) – A national accreditation program launched by the Pulmonary Hypertension Association (PHA) assures that more than 12,000 people with a life-threatening lung disease are getting care from clinicians who specialize in their often-misdiagnosed condition. Pulmonary hypertension (PH), also known as high blood pressure of the lungs, affects adults

Adding Immunoadsorption to Current Treatment for People With IPAH

2018-02-15T18:13:05+00:00 February 15th, 2018|

Study looks at a theory that adding immunoadsorption, or the process of filtering out antibodies from the blood, in addition to other PH therapies may help improve outcomes for people with idiopathic pulmonary arterial hypertension. by Phyllis Hanlon, Contributing Writer   People with idiopathic pulmonary arterial hypertension (IPAH), a type of WHO Group 1 PH (PAH,

An Overview of Pulmonary Arterial Hypertension (PAH) and Lupus

2018-02-09T03:24:39+00:00 February 9th, 2018|

WHO Group 1 PH (PAH, pulmonary arterial hypertension) can appear by itself of be associated with other medical conditions including connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). Although CTD-associated PAH is very common in people who have PAH, PAH is extremely uncommon among the many people with SLE. Because of this, a

Researchers: Collect Data at Unique Opportunity in PH Field

2018-02-01T17:37:14+00:00 February 1st, 2018|

Investigator Applications are now being accepted for the Research Room at PHA’s 2018 International PH Conference and Scientific Sessions. The Research Room helps researchers further their studies by providing the opportunity for collection of data, including phenotypic information and biological specimens, from the largest gathering of pulmonary hypertension patients in the world. Impact the field